Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Journal of Experimental Medicine Année : 2022

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.

C. Hoguin
  • Fonction : Auteur
Olivia Domanski
  • Fonction : Auteur
M. Alesandrini
  • Fonction : Auteur
N. Boddaert
  • Fonction : Auteur
T. K. Han
  • Fonction : Auteur
F. Branle
  • Fonction : Auteur

Résumé

PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.
Fichier principal
Vignette du fichier
jem_20212148.pdf (3.19 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04470886 , version 1 (21-02-2024)

Licence

Paternité - Pas d'utilisation commerciale - Partage selon les Conditions Initiales

Identifiants

Citer

G. Morin, C. Degrugillier-Chopinet, M. Vincent, A. Fraissenon, H. Aubert, et al.. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.. Journal of Experimental Medicine, 2022, Journal of Experimental Medicine, 219, ⟨10.1084/jem.20212148⟩. ⟨hal-04470886⟩
1 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More